A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia
Ramiro Garzon(Unknown), Richard M. Stone(Dana-Farber Cancer Institute)
Cited by 152
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735